Phathom Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 8, 2024 and accepted by EDGAR at Aug 8, 2024, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $7.3m | us-gaap:Revenues |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $9.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $1.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $1.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $5.9m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-01-01 to 2024-06-30 | $7.4m | us-gaap:GrossProfit |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $7.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $16.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $75.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-01-01 to 2024-06-30 | $137.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$77.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$147.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $17.8m | us-gaap:InterestExpense |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $34.9m | us-gaap:InterestExpense |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$91.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$174.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$1.56 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | −$2.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$1.56 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$2.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 58,558,145 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 58,464,813 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$139.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $86.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $276.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $304.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $319.4m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $47.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $553.2m | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $174.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-06-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-06-30 | −$233.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-093885. Last ingested by Listed: Nov 2, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.